Establishment Labs Reports Fourth Quarter and Full Year 2018 Financial Results
NEW YORK, March 20, 2019 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced its financial results for the fourth quarter and full year ended December 31, 2018.
- Full year 2018 worldwide sales of $61.2 million, representing a 76.5% increase year-over-year.
- Fourth quarter 2018 worldwide sales of $16.4 million, a 38.8% increase year-over-year.
- Ongoing revenue growth fueled by strong adoption of the Company’s Motiva Implants across addressable markets.
- Well positioned to continue capturing share in existing and new markets; poised to launch in Thailand and Taiwan in 2019.
- Reached IDE study-defined enrollment targets for the aesthetic cohorts, including primary augmentation and revision.
- Submitted the Company’s smooth anatomical tissue expander and the latest version of Motiva Ergonomix for CE Mark registration, which signal expansion into breast reconstruction and minimally invasive surgeries within breast aesthetics, respectively.
“2018 was an outstanding year for Establishment Labs as we continued to execute on our strategy of bringing our Motiva Implants to more women worldwide,” said Juan José Chacón-Quirós, Chief Executive Officer of Establishment Labs. “Our performance is the result of our clearly differentiated, innovative product portfolio and the trust physicians and patients are placing in us and our technology. With the momentum we are carrying into 2019, we should continue to deliver top line growth.”
Fourth Quarter and Full Year 2018 Financial Results
Revenues increased $4.6 million, or 38.8%, to $16.4 million for the fourth quarter of 2018, as compared to $11.8 million in the same period in 2017. Revenues for the full year ended December 31, 2018 increased $26.5 million, or 76.5%, to $61.2 million, as compared to $34.7 million for the full year ended December 31, 2018. Increased sales of Motiva Implants® were primarily driven by the continued volume growth across all addressable markets, alongside the improved business performance driven by the Company’s direct market strategies in Brazil and Europe.
Gross profit for the fourth quarter of 2018 was $9.9 million, or 60.2% of revenues, compared to gross profit of $6.6 million, or 55.6% of revenues in the same period in 2017. Gross profit for the full year ended December 31, 2018 was $36.1 million, or 59.0% of revenues, as compared to gross profit of $17.7 million, or 51.0% of revenues, in the same period in 2017. The increase in gross margin was primarily due to an increase in production volume and continued contribution of direct markets revenues with generally higher average selling prices.
Total operating expenses for the fourth quarter of 2018 increased $7.3 million, or 65.9%, to $18.5 million, as compared to $11.2 million in the same period in 2017.
Sales, general and administrative expenses for the fourth quarter of 2018 increased $6.1 million, or 70.4%, to $14.8 million, as compared to $8.7 million in the same period in 2017, due to the hiring of additional sales and administrative employees, an increase in consulting and audit fees and higher insurance costs.
Research and development expenses for the fourth quarter of 2018 increased $1.2 million, or 49.8%, to $3.7 million, as compared to $2.4 million in the same period in 2017, primarily due to investments related to the Company’s pivotal clinical trial in the United States that is required to obtain FDA approval for Motiva.
Net loss for the fourth quarter of 2018 was $10.5 million, as compared to a net loss of $7.1 million in the same period in 2017, a result of the Company’s continued growth and investments in operations to support its expected business needs.
For the full year ended December 31, 2018, net loss was $21.1 million, a decrease of $13.8 million, or 39.5%, as compared to a net loss of $34.9 million in the same period in 2017. The decrease in net loss for the full year 2018 is due to change in fair value of derivatives related to the fair value of derivatives embedded in a credit agreement entered in August 2017 with Madryn Health Partners, LP.
Total operating expenses for the full year ended December 31, 2018 were $60.0 million, an increase of $22.3 million, as compared to operating expenses of $37.7 million in the same period in 2017. The year-over-year increase in operating expenses of 59.1% is primarily attributable to the initiation of the Company’s pivotal clinical trial in the United States, the ongoing expansion of its operations costs and the associated costs of operating as a public company.
The Company’s cash balance as of December 31, 2018 was $52.6 million.
Establishment Labs will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing (877) 376-9925 (U.S. and Canada) or (629) 228-0732 (international), and using the conference ID: 9089791. In addition, the webcast will be available on the Investor Relations section of the Company's website at www.establishmentlabs.com.
A replay of the call will be available starting on March 20, 2019 at 7:30 p.m. Eastern Time, through April 19, 2019 at 7:30 p.m. Eastern Time. To access the replay, dial (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) and use the replay conference ID: 9089791. The webcast will be available on the Investor Relations section of the Company’s website for 30 days following the completion of the call.
About Establishment Labs
Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a global medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants®, the centerpiece of the MotivaImagine® platform. Motiva Implants® are produced at our two manufacturing sites that are compliant with ISO13485:2016, FDA 21 CFR 820 under the MDSAP program, and are currently sold in over 60 countries through exclusive distributors or the Company’s direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA and initiated the Motiva Implant® clinical trial in the United States in April 2018. In addition to Motiva Implants®, Establishment Labs’ product and technologies portfolio includes the Divina® 3D Simulation System, MotivaImagine® Centers and other products and services. Please visit the website for additional information: www.establishmentlabs.com.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). You can find many (but not all) of these statements by looking for words such as “approximates,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “would,” “may” or other similar expressions in this press release, and includes statements related to the expected growth in sales of Motiva Implants, product development and the PMA clinical trial currently being conducted to obtain approval of Motiva Implants in the United States. Any statements that refer to projections of our future financial or operating performance, anticipated trends in our business, our goals, strategies, focus and plans, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, are forward-looking statements. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995. We caution investors that any forward-looking statements presented in this report, or that we may make orally or in writing from time to time, are expressions of our beliefs and expectations based on currently available information at the time such statements are made. Such statements are based on assumptions, and the actual outcome will be affected by known and unknown risks, trends, uncertainties and factors that are beyond our control. Although we believe that our assumptions are reasonable, they are not guarantees of future performance, and some will inevitably prove to be incorrect. As a result, our actual future results may differ from our expectations, and those differences may be material. Factors that could cause or contribute to these differences include, among others, those risks and uncertainties discussed in the Company’s Form S-1, quarterly reports on Form 10-Q, and other filings made by the Company with the Securities and Exchange Commission. The risks included in those documents are not exhaustive, and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for us to predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We are not undertaking any obligation to update any forward-looking statements. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on known results and trends at the time they are made, to anticipate future results or trends.
ESTABLISHMENT LABS HOLDINGS INC.
Consolidated Statements of Operations
(In thousands, except share and per share data)
|Three Months Ended|
|Year Ended December 31,|
|Cost of revenue||6,524||5,248||25,090||16,979|
|Sales, general and administrative||14,833||8,707||47,295||30,821|
|Research and development||3,661||2,444||12,687||6,864|
|Total operating expenses||18,494||11,151||59,982||37,685|
|Loss from operations||(8,621||)||(4,588||)||(23,864||)||(19,983||)|
|Change in fair value of derivative instruments||(51||)||(324||)||15,894||(2,428||)|
|Change in fair value of contingent consideration||(281||)||—||(1,727||)||—|
|Initial public offering expenses||—||—||—||(1,585||)|
|Other income (expense), net||850||(374||)||(2,388||)||(395||)|
|Loss before income taxes||(10,362||)||(7,064||)||(20,883||)||(34,792||)|
|Benefit (provision) for income taxes||(152||)||(69||)||(215||)||(105||)|
|Basic and diluted loss per share||$||(0.52||)||$||(2.00||)||$||(1.22||)||$||(3.41||)|
|Weighted average outstanding shares used for basic and diluted|
net loss per share
ESTABLISHMENT LABS HOLDINGS INC.
Consolidated Balance Sheets
(In thousands, except share data)
|Accounts receivable, net of allowance for doubtful accounts of $926 and $1,512||17,648||13,108|
|Prepaid expenses and other current assets||4,303||2,237|
|Total current assets||99,435||39,382|
|Property and equipment, net of accumulated depreciation of $5,230 and $3,179||12,913||13,500|
|Intangible assets, net of accumulated amortization of $1,213 and $573||3,445||3,401|
|Other non-current assets||315||272|
|Liabilities and shareholders’ equity (deficit)|
|Notes payable related party, including accrued interest||—||4,921|
|Note payable, Madryn, net of debt discount and issuance costs||—||19,167|
|Madryn put option||—||20,302|
|Madryn call option||—||360|
|Other liabilities, short term||4,083||1,228|
|Total current liabilities||16,447||57,435|
|Note payable, Madryn, net of debt discount and issuance costs||22,322||—|
|Madryn put option||4,768||—|
|Other liabilities, long term||3,551||4,673|
|Total shareholders’ equity (deficit)||69,485||(5,013||)|
|Total liabilities and shareholders’ equity (deficit)||$||116,573||$||57,095|
Investor Relations and Media Contact